Last updated: October 15, 2026
Nuvigil, Teva Pharmaceutical Industries' branded armodafinil product, moved from a differentiated wakefulness drug to a mature generic market after U.S. generic entry in 2016. Its commercial decline reflects patent-settlement timing, conversion from branded to generic prescriptions, competition from modafinil and newer wake-promoting therapies, and the loss of Teva's ability to sustain premium pricing. Nuvigil remains FDA-approved, but its economic value is now concentrated in generic armodafinil rather than the branded product.
What is Nuvigil and what indications does it treat?
Nuvigil is the brand name for armodafinil, the R-enantiomer of modafinil. The FDA approved Nuvigil in June 2007 under NDA 021875. Cephalon developed and commercialized the product before Teva acquired Cephalon in 2011.[1][2]
Nuvigil is approved for excessive sleepiness associated with:
- Narcolepsy
- Obstructive sleep apnea
- Shift work disorder
The product is available as oral tablets in 50 mg, 150 mg, 200 mg, and 250 mg strengths. It is a Schedule IV controlled substance in the United States because of its potential for abuse and dependence.[1]
Nuvigil does not treat the underlying airway obstruction in obstructive sleep apnea. The FDA label states that it should be used as an adjunct to primary treatment of the obstruction, such as continuous positive airway pressure.[1]
Nuvigil compared with Provigil
Provigil contains racemic modafinil, while Nuvigil contains armodafinil. Armodafinil has a longer terminal half-life than the S-enantiomer, which supported positioning around sustained wakefulness and once-daily administration.[1]
| Attribute |
Nuvigil |
Provigil |
| Active ingredient |
Armodafinil |
Modafinil |
| Molecular form |
R-enantiomer |
Racemic mixture |
| FDA approval |
2007 |
1998 |
| Primary use |
Excessive sleepiness |
Excessive sleepiness |
| Dosage form |
Oral tablets |
Oral tablets |
| Brand owner |
Teva, following Cephalon acquisition |
Teva, following Cephalon acquisition |
| Generic status |
Generic armodafinil available |
Generic modafinil available |
| Commercial position |
Mature generic market |
Mature generic market |
How large was the Nuvigil market before generic entry?
Nuvigil generated approximately $300 million in annual U.S. sales during its commercial peak, according to Teva and Cephalon financial disclosures.[2][3] The product became one of Cephalon's principal growth assets after Provigil began approaching the end of its main patent protection.
Nuvigil benefited from several commercial factors:
- It addressed the same broad wakefulness market as Provigil.
- It gave Cephalon a follow-on product with a later patent position.
- It allowed physicians and patients to transition from modafinil to armodafinil.
- It supported continued commercial presence in sleep medicine after Provigil faced generic pressure.
The product did not replace Provigil's full revenue base. Nuvigil had a narrower period of branded exclusivity and faced payer resistance to switching patients from lower-cost modafinil. Its revenue also depended heavily on chronic use, reimbursement, and a specialty market with several alternative therapies.
Nuvigil revenue trajectory
Public-company reporting generally disclosed Nuvigil sales within broader product categories or geographic segments rather than providing a complete, consistent annual U.S. series. The available commercial pattern is clear:
| Period |
Market position |
Financial effect |
| 2007-2010 |
Newly launched branded therapy |
Rapid prescription and revenue growth |
| 2011-2013 |
Mature branded product under Teva ownership |
Approximately $300 million annual sales range |
| 2014-2015 |
Pre-generic erosion and settlement preparation |
Pricing and prescription pressure increased |
| 2016 onward |
Generic armodafinil entry |
Sharp branded revenue contraction |
| 2020s |
Mature generic market |
Limited branded economic contribution |
The key inflection point was generic entry, not loss of FDA approval. Teva retained the product's regulatory authorization, but the commercial value of the brand declined as pharmacies and payers substituted generic armodafinil.
When did Nuvigil lose exclusivity?
Nuvigil's meaningful U.S. market exclusivity ended when generic armodafinil became available in 2016. The date resulted from patent litigation settlements rather than a simple expiration-driven launch.
The principal Nuvigil patent was U.S. Patent No. 7,132,570, which covered armodafinil and related methods of use. Generic applicants filed Paragraph IV certifications challenging listed Nuvigil patents. Teva reached settlements that permitted generic launch before the latest asserted patent expiration.[4][5]
Nuvigil exclusivity timeline
| Date |
Event |
| June 15, 2007 |
FDA approved Nuvigil for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder.[1] |
| 2011 |
Teva completed its acquisition of Cephalon.[2] |
| 2012-2014 |
Generic applicants pursued Paragraph IV challenges to Nuvigil patents.[4][5] |
| 2015 |
FDA approval activity for generic armodafinil accelerated.[6] |
| 2016 |
Generic armodafinil entered the U.S. market under settlement-related launch arrangements.[4][5] |
| 2020s |
Brand and generic products competed in a mature market. |
The FDA's three-year exclusivity for the new clinical investigations supporting Nuvigil had expired well before generic launch. Patent protection, not regulatory exclusivity, controlled the commercial timing.[1][6]
What patents protected Nuvigil?
Nuvigil's protection relied primarily on composition, method-of-use, and formulation-related intellectual property. The estate was narrower than a portfolio built around a new chemical entity because armodafinil is closely related to the previously marketed modafinil molecule.
Key patent categories
| Patent category |
Commercial purpose |
Competitive relevance |
| Armodafinil composition patents |
Protect the active enantiomer |
Core protection against generic armodafinil |
| Method-of-use patents |
Cover treatment of excessive sleepiness and related conditions |
Supported infringement claims against abbreviated new drug applications |
| Formulation patents |
Cover tablet composition or release characteristics |
Potentially delayed specific generic products |
| Manufacturing patents |
Cover synthesis, purification, or crystallization |
Could increase technical entry costs but usually did not block all market entry |
U.S. Patent No. 7,132,570 was the central patent associated with Nuvigil's armodafinil protection. Public patent records and Orange Book data should be read together because a patent's nominal expiration date does not necessarily equal the date of market exclusivity. Patent-term adjustment, pediatric exclusivity, settlement licenses, and the scope of the claims can change the practical launch date.[4][7]
What was the Orange Book status of Nuvigil?
Nuvigil was listed in the FDA Orange Book with patents covering armodafinil and related approved uses. Generic applicants could file Paragraph IV certifications against those patents under the Hatch-Waxman Act.[6][7]
The relevant regulatory structure was:
- Teva held the reference listed drug position for Nuvigil.
- ANDA applicants certified that listed patents were invalid, unenforceable, or not infringed.
- Paragraph IV notices triggered patent litigation.
- The first qualifying ANDA filer could potentially obtain 180-day generic exclusivity.
- Settlements established commercial launch dates for generic applicants.
The Orange Book did not by itself determine whether Teva would retain market share. Once generic launch occurred, payer substitution and multi-source purchasing rapidly reduced the brand's pricing power.
Which companies challenged Nuvigil patents?
Generic companies that pursued armodafinil opportunities included major ANDA filers such as Apotex, Lupin, Mylan, Sandoz, and related applicants identified in federal litigation and regulatory records.[4][5]
The litigation strategy followed the standard Paragraph IV model. Generic companies challenged patent validity or infringement while seeking approval before the final listed patent term. Teva and Cephalon used patent litigation and settlement agreements to control the timing of commercial entry.
The economic result was a delayed but ultimately concentrated generic launch. Several suppliers entered or prepared to enter the market around the same period, which limited the durability of any individual generic's price premium.
What patent litigation affected Nuvigil?
Nuvigil litigation centered on the validity and scope of Teva and Cephalon's armodafinil patents. The cases involved questions common to enantiomer and follow-on drug litigation:
- Whether the claimed armodafinil form was patentably distinct from modafinil
- Whether the claims were anticipated or obvious
- Whether generic products infringed the asserted claims
- Whether formulation or method-of-use claims could block an ANDA
- Whether settlement terms delayed competition beyond the statutory patent term
The litigation did not produce a durable barrier to generic entry. Teva's settlements converted uncertain litigation outcomes into negotiated launch dates. That approach protected a defined period of branded revenue but reduced the potential upside from maintaining a full patent-based monopoly through trial and appeal.
How strong was the Nuvigil patent estate?
Nuvigil's patent estate was commercially effective but not structurally strong by the standards of a platform medicine with multiple independent composition, formulation, device, and manufacturing barriers.
Strengths
- The product had a distinct active enantiomer that supported composition-based claims.
- Teva could use Hatch-Waxman litigation to delay generic launch.
- Nuvigil had three approved indications, creating multiple method-of-use positions.
- The product's established clinical use supported continued demand after patent expiry.
Weaknesses
- Armodafinil was chemically related to the earlier modafinil product.
- Generic manufacturers could target the active ingredient directly.
- Oral tablets had limited device or delivery-system complexity.
- Multiple generic suppliers reduced the value of secondary formulation claims.
- The commercial franchise had limited protection against therapeutic substitution.
The practical patent strength was therefore moderate: sufficient to support several years of branded sales, but insufficient to preserve a high-margin franchise after generic armodafinil became available.
How did generic entry change Nuvigil's market dynamics?
Generic entry changed the market from branded differentiation to price-based procurement. The primary effects were:
- Lower average selling prices
- Pharmacy-level substitution
- Reduced direct-to-consumer and physician promotion
- Greater use of generic armodafinil by insurers
- Declining brand prescriptions
- Increased dependence on wholesaler and payer contracts
Generic armodafinil competes with generic modafinil, which is usually less expensive and has a longer prescribing history. Nuvigil therefore faced two layers of substitution: generic copies of armodafinil and the older generic modafinil product.
Generic launch scenarios
| Scenario |
Market effect |
| Single generic entrant |
Temporary price resilience and possible 180-day exclusivity benefit |
| Several entrants |
Rapid price erosion and reduced pharmacy preference for the brand |
| Brand-authorized generic |
Retains some supply-chain control but limits branded economics |
| Continued brand prescribing |
Supports a small premium segment, mainly for patients stable on Nuvigil |
| Payer-mandated substitution |
Accelerates brand revenue loss |
The expected commercial outcome after 2016 was a steep decline in branded sales followed by a lower-value, higher-volume generic market.
What competition affects Nuvigil today?
Nuvigil competes with several categories:
Generic modafinil
Generic modafinil remains the closest substitute. It is available in a broader prescribing base and generally benefits from lower cost.
Solriamfetol
Sunosi, developed by Jazz Pharmaceuticals, was approved in 2019 for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It competes on mechanism, clinical positioning, and specialty promotion.[8]
Pitolisant
Wakix, developed by Harmony Biosciences, was approved for excessive daytime sleepiness in narcolepsy and later for cataplexy. Its noncontrolled-substance status in the United States provides a commercial point of differentiation.[9]
Sodium oxybate products
Xyrem and Xywav address narcolepsy symptoms through a different pharmacologic approach. Xywav's lower-sodium formulation created a differentiated product position in the narcolepsy market.[10]
Nonpharmaceutical treatment
For obstructive sleep apnea, CPAP and other airway therapies remain the primary treatment. This limits the addressable market for wakefulness drugs because Nuvigil is intended to treat residual sleepiness, not the obstructive disorder itself.[1]
Is there biosimilar risk for Nuvigil?
There is no biosimilar risk because Nuvigil is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive threat is generic armodafinil under the ANDA pathway.
This distinction matters commercially. Generic applicants can generally rely on pharmaceutical equivalence and bioequivalence rather than conducting the comparative clinical development required for a biosimilar. The resulting entry process is faster and usually produces more immediate price competition.
What is Nuvigil's current FDA and commercial status?
Nuvigil remains an FDA-approved armodafinil product, while generic armodafinil is available through multiple manufacturers.[1][6] The commercial market is mature, and the branded product no longer has the growth profile associated with its pre-generic period.
The main business risks are:
- Brand-to-generic substitution
- Generic modafinil price competition
- Reduced physician promotion
- Payer restrictions
- Therapeutic substitution by Sunosi and Wakix
- Limited ability to extend exclusivity through new formulations
- Controlled-substance handling requirements
The principal residual value lies in generic supply, manufacturing efficiency, distribution, and established prescribing demand. It does not lie in a substantial remaining branded patent moat.
What revenue exposure did Teva face from Nuvigil?
Teva's direct exposure was meaningful before generic launch because Nuvigil was a mid-sized specialty product with annual sales near the $300 million range. The exposure was smaller than the company's largest products but material within the legacy Cephalon portfolio.[2][3]
The financial trajectory had three stages:
- Growth after the 2007 approval.
- Stable or moderately declining sales before generic entry.
- Rapid revenue erosion after generic armodafinil launched.
The acquisition of Cephalon gave Teva a diversified specialty portfolio, but it also exposed Teva to a cluster of products approaching patent expiry. Nuvigil's loss of exclusivity formed part of the broader erosion affecting Teva's branded respiratory, central nervous system, and specialty medicines portfolio.
What licensing and settlement agreements affected Nuvigil?
The most important commercial agreements were Paragraph IV patent settlements with generic applicants. These agreements typically provided a defined generic launch date and resolved litigation risk without requiring a final judgment on every patent claim.[4][5]
There is no major standalone licensing transaction that transformed Nuvigil's long-term economics. The material value-transfer mechanism was the settlement structure governing generic access.
Settlement economics depended on:
- The agreed launch date
- The number of generic entrants
- Any authorized-generic rights
- Patent claims released
- Supply or royalty provisions
- The ability of first filers to obtain 180-day exclusivity
The settlement protected a finite period of branded sales but could not prevent eventual multi-source generic competition.
How does Nuvigil compare with newer wakefulness drugs?
| Product |
Company |
FDA status |
Competitive distinction |
Patent risk |
| Nuvigil |
Teva |
Approved |
Armodafinil; established use |
Mature generic competition |
| Provigil |
Teva |
Approved |
Modafinil; older market presence |
Mature generic competition |
| Sunosi |
Jazz |
Approved |
Solriamfetol; wakefulness-focused positioning |
Branded patent and exclusivity exposure |
| Wakix |
Harmony |
Approved |
Pitolisant; noncontrolled-substance profile |
Later-stage branded protection |
| Xywav |
Jazz |
Approved |
Lower-sodium oxybate formulation |
Formulation and method-of-use protection |
Nuvigil's main advantage is familiarity and availability. Its main disadvantage is the absence of meaningful exclusivity and the availability of lower-cost substitutes.
Key Takeaways
- Nuvigil is branded armodafinil, approved by the FDA in 2007 for excessive sleepiness linked to narcolepsy, obstructive sleep apnea, and shift work disorder.
- Teva acquired Nuvigil through its 2011 acquisition of Cephalon.
- Peak annual sales were approximately $300 million based on public company disclosures.
- Generic armodafinil entered the U.S. market in 2016 following Paragraph IV litigation and settlement activity.
- The product's central patent estate was commercially effective but not strong enough to prevent eventual generic competition.
- Nuvigil has no biosimilar risk because it is a small-molecule drug.
- Generic armodafinil and generic modafinil now define the market economics.
- Sunosi, Wakix, and Xywav create additional branded competition in sleep and wakefulness disorders.
- Teva's residual value is concentrated in generic supply and established demand, not in branded exclusivity.
- The product's revenue trajectory is consistent with a specialty medicine that experienced rapid post-LOE erosion.
FAQs
Is Nuvigil still available by prescription?
Yes. Nuvigil and generic armodafinil are FDA-approved prescription products, subject to controlled-substance requirements and the prescribing rules applicable to armodafinil.
Is armodafinil more profitable than modafinil?
Branded armodafinil historically commanded a premium, but generic armodafinil competes with generic modafinil. Profitability depends on manufacturing cost, supplier count, payer contracts, and dosage strength.
Did Teva launch a generic version of Nuvigil?
Teva has participated in the armodafinil market, while multiple generic manufacturers have supplied FDA-approved generic armodafinil. The commercial market is not dependent on the Nuvigil brand.
Does Nuvigil have an authorized generic?
An authorized-generic determination depends on the specific product, supplier, and commercial period. FDA approval of generic armodafinil does not by itself establish that a particular product was an authorized generic distributed by the brand owner.
Can Nuvigil patents block generic armodafinil today?
The major commercial barrier has already been overcome. Generic armodafinil is available in the United States, so historical Nuvigil patents no longer provide an effective market-wide block to generic entry.
References
- U.S. Food and Drug Administration. (2007). Nuvigil (armodafinil) prescribing information. FDA.
- Teva Pharmaceutical Industries Ltd. (2011). Annual report 2011. Teva.
- Cephalon, Inc. (2010). Annual report 2010. Cephalon.
- U.S. District Court for the District of Delaware. (2012-2015). Cephalon, Inc. v. Apotex Corp. and related Nuvigil patent litigation records.
- Federal Trade Commission. (2013). Authorized generic and pharmaceutical patent settlement materials. FTC.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Nuvigil and armodafinil products. FDA.
- U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,132,570: Methods of treating sleep disorders with armodafinil. USPTO.
- U.S. Food and Drug Administration. (2019). Sunosi (solriamfetol) prescribing information. FDA.
- U.S. Food and Drug Administration. (2019). Wakix (pitolisant) prescribing information. FDA.
- U.S. Food and Drug Administration. (2020). Xywav (calcium, magnesium, potassium, and sodium oxybates) prescribing information. FDA.
